Clinical Trials
7 trialsNCT07536815 2026-04-27
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
CytoDyn, Inc.
Available
NCT04085653 2026-04-14
Managed Access Programs for BYL719, Alpelisib
Novartis
Available
NCT05038631 2026-04-13
Managed Access Programs for LEE011, Ribociclib
Novartis
Available
NCT04091295 2026-03-04
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04313075 2025-07-15
A Compassionate Use Study of Leronlimab in Breast Cancer
CytoDyn, Inc.
No longer available
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing